Compare Bristol-Myers Squibb Co (BMY) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Valero Energy Corporation — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Valero Energy Corporation trades at $301.3 (market cap $89.50B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | VLO | |
|---|---|---|
Market Cap | $116.30B | $89.50B |
Sector | Health | Energy |
52-Week High | $62.37 | $301.43 |
52-Week Low | $42.60 | $131.77 |
Enterprise Value | $152.24B | $95.26B |
Dividend Yield | 4.42% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Valero Energy (VLO) trades at $295.79, up 5.38% in the last session, reflecting strong momentum amid bullish technical signals and positive earnings surprises. The stock's valuation metrics, including a P/E of 20.5 and P/S of 0.69, appear reasonable relative to historical levels, while profitability remains solid with a 17.72% ROE. Recent news highlights VLO's exposure to elevated refining margins and strong fuel demand, particularly benefiting its Gulf Coast operations.
The outlook for VLO is supported by robust refining fundamentals and a favorable analyst consensus, though risks include volatile energy markets and declining revenue trends. Upside potential exists if the company continues to exceed earnings expectations and capitalizes on tight product supplies, but investors should monitor margin pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
